Cingulate Cortex in Schizophrenia: Its relation with negative symptoms and psychotic onset. A review study

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 22, 2014, Pages 3354-3367

  Bersani, F S ^a   Minichino, A ^a   Fojanesi, M ^a   Gallo, M ^a   Maglio, G ^a   Valeriani, G ^a   Biondi, M ^a   Fitzgerald, P B ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Monash Alfred Psychiatry Research Centre Alfred and Central Clinical School Monash University ^*  (Australia)

Author keywords

Cingulate cortex; Negative symptoms; Psychotic onset; Schizophrenia

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; N ACETYLASPARTIC ACID;

ANTERIOR CINGULATE; ARTICLE; BOLD SIGNAL; BRAIN NERVE CELL; COCHRANE LIBRARY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HIGH RISK PATIENT; HUMAN; HYPOACTIVITY; MEDICAL LITERATURE; MEDLINE; NEGATIVE SYNDROME; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURED INTERVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VOXEL BASED MORPHOMETRY; WEB OF SCIENCE; WHITE MATTER LESION;

EID: 84903646187     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. MUESER KT, BELLACK AS, DOUGLAS MS, WADE JH. Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology. Psychiatry Res 1991; 37: 281-296.
2. CASCELLA NG, FIELDST ONE SC, RAO VA, PEARLSON GD, SAWA A, SCHRETLEN DJ. Gray-matter abnormalities in deficit schizophrenia. Schizophr Res 2010; 120: 63-70.
3. PAUS T, COLLINS DL, EVANS AC, LEONARD G, PIKE B, ZIJDENBOS A. Maturation of white matter in the human brain: a review of magnetic resonance studies. Brain Res Bull 2001; 54: 255-266.
4. DREVETS WC, ONGUR D, PRICE JL. Neuroimag ing abnormalities in the subgenual prefrontal cortex: implications for the anterior cingulate cortex in schizophrenia pathophysiology of familial mood disorders. Mol Psychiatry 1998; 3: 190-191, 220-226.
5. ) VOGT BA, NIMCHINSKY EA, VOGT LJ, HOF PR. Human cingulated cortex: surface features, flat maps, and cytoarchitecture. J Comp Neurol 1995; 359: 490-506.
6. PAUS T. Primate anterior cingu late cortex: where motor control, drive and congition interface. Nat Rev Neurosci 2001; 2: 417-424.
7. FORNITO A, YUCEL M, DEAN B, WOOD SJ, PANTELIS C. Anatomical abnormalities of the anterio r cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull 2009; 35: 973-993.
8. ANDREASEN NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 7: 49-58.
9. ANANTH J, DJENDERDJIAN A, SHAMASUNDER P, COSTA J, HERRERA J, SRAMEK J. Negative symptoms: psychopathological models. J Psychiatry Neurosci 1991; 16: 12-18.
10. POLLI E, BERSANI FS, DE ROSE C, LIBERATI D, VALERIANI G, WEISZ F, COLLETTI C, ANASTASIA A, BERSANI G. Facial Action Coding System (FACS): an instrument for the objective evaluation of facial expression and its potential applic ations to the study of schizophrenia. Riv Psichiatr 2012; 47: 126-138.
11. BERSANI G, BERSANI FS, VALERIANI G, ROBIONY M, ANASTASIA A, COLLETTI C, LIBERATI D, CAPRA E, QUARTINI A, POLLI E. Comparison of facial expression in patients with obsessive-compulsive disorder and schizophrenia using the Facial Action Coding System: a preliminary study. Neuropsychiatr Dis Treat 2012; 8: 537-547.
12. BERSANI, G, CLEMENTE R, GHERARDELLI S, BERSANI FS, MANUALI G. Obstetric complications and neurological soft signs in male patients with schizophrenia. Acta Neuropsychiatrica 2012; 24: 344-348.
13. TAMMINGA CA, BUCHANAN RW, GOLD JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998; 13: S21-26.
14. CROW TJ. Brain chan ges and negative symptoms in schizophrenia. Psychopathology 1995; 28: 18-21.
15. BUCHANAN R, JAVITT D, MARDER S, SCHOOLER N, GOLD J, MCMAHON RP, HERESCO-LEVY U, CARPENTER WT. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairment. Am J Psychiatry 2007; 164: 1593-1602.
16. BERSANI FS, CAPRA E, MINICHINO A, PANNESE R, GIRARDI N, MARINI I, DELLE CHIAIE R, BIONDI M. Factors affecting interindividual differences in clozapine response: a review and case report. Hum Psychop harmacol 2011; 26: 177-187.
17. LIBERMAN J, STROUP T, MCEVOY J SWARTZ MS, ROSENHECK RA, PERKINS DO, KEEFE RS, DAVIS SM, DAVIS CE, LEBOWITZ BD, SEVERE J, HSIAO JK; CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS (CATIE) INVESTIGATORS. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
18. PANNESE R, MINICHINO A, PIGNATELLI M, DELLE CHIAIE R, BIONDI M, NICOLETTI F. Evidences on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough " in pharmacological treatment. Riv Psichiatr 2012; 47: 149-169.
19. GIRARDI P, RAPINESI C, CUOMO I, KOTZALIDIS GD, DEL CASALE A, SERATA D, CAMPI S, CAL ORO M, DE CHIARA L, TAMORRI SM, SCATENA P, CACCIA F, BERSANI FS, CARBONETTI P, VENTO A, DIMITRI-VALENTE G, TATARELLI R, FENSORE C, FERRACUTI S, ANGELETTI G. Life-saving electroconvulsive therapy in a pa tient with nearlethal catatonia. Riv Psichiatr 2012; 47: 535-537.
20. BRIER A, SCHRIEBER J, DYER J, PICKAR D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48: 239-246.
21. MILEV P, HO B, ARNDT S, ANDREASEN N. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7 year follow up. Am J Psychiatry 2005; 162: 495-506.
22. CARPENTER WT JR, HEINRICHS DW, WAGMAN AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583.
23. NIBUYA M, KANBA S, SEKIYA U, SUZUKI E, MATSUO Y, KINOSHITA N, SHINTANI F, YAGI G, ASAI M. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 1995; 38: 50-56.
24. ANDREASEN NC, OLSEN S, DENNERT JW, SMITH MR. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry 1982; 139: 297-302.
25. SEMKOVSKA M, BEDARD MA, STIP E. Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neurops ychological knowledge and ecological perspectives. Encephale 2001; 27: 405-415.
26. BUCHSBAUM MS, HAZLETT EA. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 1998; 24: 343-364.
27. WOLKIN A, SANFILIPO M, WOLF AP, ANGRIST B, BRODIE JD, ROTROSEN J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 959-965.
28. SALVIATI M, BERSANI FS, MACRÍ F, FOJANESI M, MINICHINO A, GALLO M, DE MICHELE F, CHIAIE RD, BIONDI M. Capgras-like syndrome in a patient with an acute urinary tract infection. Neuropsychiatr Dis Treat 2013; 9: 139-142.
29. YUNG AR, PHILLIPS LJ, MCGORRY PD, MCFARLANE CA, FRANCEY S, HARRIGAN S, PATTON GC, JACKSON HJ. Prediction of psycho sis: a step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998; 172: 14-20.
30. YUNG AR, PHILLIPS LJ, YUEN HP, FRANCEY SM, MCFARLANE CA, HALLGREN M, MCGORRY PD. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 2003; 60: 21-32.
31. YUNG AR, PHILLIPS LJ, YUEN HP, MCGORRY PD. Risk factors for psychosis in an Ultra High Risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-142.
32. BENES FM. Relationship of cingulate cortex to schizophrenia and other psychiatric disorders. In: Vogt BA, Gabriel M, editors. Neurobiology of Cingulate Cortex and Limbic Thalamus: A Comprehensive Handbook. Boston: Birkhauser, 1993; pp. 580-605.
33. WOOD SJ, PANTELIS C, VELAKOUL IS D, YÜCEL M, FORNITO A, MCGORRY PD. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr Bull 2008; 34: 322-329.
34. GASPARO TTI R, VALSECCHI P, CARLETTI F, GALLUZZO A, LISERRE R, CESANA B, SACCHETTI E. Reduced fractional anisotropy of corpus callosumin first-contact, antipsychotic drug-naive patients with schizophrenia. Schizophr Res 2009; 108: 41-48.
35. BLOEMEN OJ, DE KONING MB, SCHMITZ N, NIEMAN DH, BECKER HE, DE HAAN L, DINGEMANS P, LINSZEN DH, VAN AMELSVOORT TA. White-matter markers for psychosis in a prospective ul trahigh-risk cohort. Psychol Med 2009; 40: 1297-1304.
36. LORD LD, ALLEN P, EXPERT P HOWES O, LAMBIOTTE R, MCGUIRE P, BOSE SK, HYDE S, TURKHEIMER FE. Characterization of the anter ior cingulate's role in the at-risk mental state using graph theory. Neuroimage 2011; 56: 1531-1539.
37. PANTELIS C, VELAKOULIS D, MCGORRY PD, WOOD SJ, SUCKLING J, PHILLIPS LJ, YUNG AR, BULLMORE ET, BREWER W, SOULSBY B, DESMOND P, MCGUIRE PK. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet 2003; 361: 281-288.
38. BORGWARDT SJ, RIECHER-RÖ SSLER A, DAZZAN P, CHITNIS X, ASTON J, DREWE M, GSCHWANDTNER U, HALLER S, PFLÜGER M, RECHSTEINER E, D'SOUZA M, STIEGLITZ RD, RADÜEW, MCGUIRE PK. Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry 2007; 61: 1148-1156.
39. JOB DE, WHALLEY HC, MCCONNELL S, GLABUS M, JOHNSTONE EC, LAWRIE SM. Voxel-based morpho metry of grey matter densities in subjects at high risk of schizophrenia. Schizophr Res 2003; 64: 1-13.
40. JOB DE,WHALLEY HC,JOHNSTONE EC,.LAWRIE SM. Grey matter changes over time in high risk subjects developing schizophrenia Neuroimage 2005 25 1023-1030.
41. FORNITO A, YUNG AR, WOOD SJ, PHILLIPS LJ, NELSON B, COTTON S, VELAKOULIS D, MCGORRY PD, PANTELIS C, YÜCE L M. Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: an mri study of ultra-high-risk individuals. Biol Psychiatry 2008; 64: 758-765.
42. YUNG AR, YUEN HP, MCGORRY PD, PHILLIPS LJ, KELLY D, DELL'OLIO M, FRANCEY SM, COSGRAVE EM, KILLACKEY E, STANFORD C, GODFREY K, BUCKBY J. Mapping the onset of psychosis: The comprehensive assessment of at-risk mental states. Aust N Z J Psych iatry 2005; 39: 964-971.
43. YUNG A, PHILLIPS L, MCGORRY PD. London, England: Taylor & Francis; 2004. Treating Schizophrenia in the Prodromal Phase.
44. AMODIO DM, FRITH CD. Meeting of minds: The medial frontal cortex and social cognition. Nat Rev Neurosci 2006; 7: 268-277.
45. MOLLER P, HUSBY R. The initial prodrome in schizophrenia: Searching for naturalistic core dimensions of experience and behavior. Schizophr Bull 2000; 26: 217-232.
46. MARJORAM D, MILLER P, MCINTOSH AM, CUNNINGHAM OWENS DG, JOHNSTONE EC, LAW RIE S. A neuropsychological investigation into 'Theory of Mind' and enhanced risk of schizophrenia. Psychiatry Res 2006; 144: 29-37.
47. MARJORAM D, JOB DE, WHALLEY HC, GOUNTOUNA VE, MCINTOSH AM, SIMONOTTO E, CUNNINGHAM-OWENS D, JOHNSTONE EC, LAWRIE S. A visual joke fMRI investigation into Theory of Mind and enhanced risk of schizophrenia. NeuroImage 2006; 31: 1850-1858.
48. FORNITO A, YÜCEL M, WOOD SJ, ADAMSON C, VELAKOULIS D, SALING MM, MCGORRY PD, PANTELIS C. Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Hum Brain Mapp 2008; 29: 478-489.
49. KESHAVAN MS, SCHOOLER NR. First-episode studies in schizophrenia: Criteria and characterization. Schizophr Bull 1992; 18: 491-513.
50. GIEDD JN. Structural magnetic resonance imaging of the adolescent brain. Ann NY Acad Sci 2004; 1021: 77-85.
51. KUPERBERG GR, BROOME MR, MCGUIRE PK, DAVID AS, EDDY M, OZAWA F, GOFF D, WEST WC, WILLIAMS SC, VAN DER KOUWE AJ, SALAT DH, DALE AM, FISCHL B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry 2003; 60: 878-888.
52. DEVINSKY O, MORRELL MJ, VOGT BA. Contributions of anterior cingulate cortex to behaviour. Brain 1995; 118: 279-306.
53. CANNON M, JONES P, GILVARRY C, RIFKIN L, MCKENZIE K, FOERSTER A, MURRAY RM. Premorbid social functioning in schizophrenia and bipolar disorder: Similarities and differences. Am J Psychiatry 1997; 154: 1544-1550.
54. KERNS JG. Positive schizotypy and emotion processing. J Abnorm Psychol 2005; 114: 392-401.
55. BENES FM, SORENSEN I, VINCENT SL, BIRD ED, SATHI M. Increased density of glutamate immunoreactive vertical processes in superficial laminae in ci ngulate cortex of schizophrenic brain. Cereb Cortex 1992; 2: 503-512.
56. ALLMAN JM, HAKEEM A, ERWIN JM, NIMCHINSKY E, HOF P. The anterior cingulate cortex. The evolution of an interface between emotion and cognition. Ann N Y Acad Sci 2001; 935: 107-117.
57. WATSON KK. Evolution, risk, and neural representation. Ann N Y Acad Sci 2008; 1128: 8-12.
58. NIMCHINSKY EA, VOGT BA, MORRISON JH, HOF PR. Spindle neurons of the human anterior cingulate cortex. J Comp Neurol 1995; 355: 27-37.
59. SEELEY WW, CARLIN DA, ALLMAN J M MACEDO MN, BUSH C, MILLER BL, DEARMOND SJ. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol 2006; 60: 660-667.
60. KAUFMAN JA, PAUL LK, MANAYE KF GRAN STEDT AE, HOF PR, HAKEEM AY, ALLMAN JM. Selective reduction of Von Economo neuron number in agenesis of the corpus callosum. Acta Neuropathol 2008; 116: 479-489.
61. PAUC R,YOUNG A The history of von Economo neurons (VENs) and their possible role in neurodevelopmental disorders: a literature review Clin Chiropract 2009 12 101-108.
62. BRUNE M, SCHOBEL A, KARAU R, BENALI A, F AUSTMANN PM, JUCKEL G, PETRASCH-PARWEZ E. Von Economo neuron density in the anterior cingulate cortex is reduced in early onset schizophrenia. Acta Neuropathol 2010; 119: 771-778.
63. POTKIN SG, ALVA G, FLEMING K, ANAND R, KEATOR D, CARREON D, DOO M, JIN Y, WU JC, FALLON JH. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry 2002; 159: 227-237.
64. SABRI O, ERKWOH R, SCHRECKENBERGER M, CREMERIUS U, SCHULZ G, DICKMANN C, KAISER HJ, STEINMEYER EM, SASS H, BUELL U. Regional cerebral blood flow and negative/positi ve symptoms in 24 drug-naive schizophrenics. J Nucl Med 1997; 38: 181-188.
65. ASHTON L, BARNES A, LIVINGSTON M, WYPER D. Cingulate abnormalities associated with PANSS negative scores in first episode schizophrenia. Behav Neurol 2000; 12: 93-101.
66. BENTON AL. Differential effects in frontal lobe disease. Neuropsychologia 1968; 6: 53-60.
67. GALENO R, MOLINA M, GUIRAO M, ISOARDI R. Severity of negative symptoms in schizophrenia correlated to hyperactivity of the left globus pallidus and the right claustrum. A PET study. World J Biol Psychiatry 2004; 5: 20-25.
68. LAHTI AC, WEILER MA, HOLCOMB HH, TAMMINGA CA, CARPENTER WT, MCMAHON R. Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology 2 006; 31: 221-230.
69. BATES TE, STRANGWARD M, KEELAN J, DAVEY GP, MUNRO PM, CLARK JB. Inhibition of N-Acetylaspartate production: Implications for 1H MRS studies in vivo. Neuroreport 1996 ; 7: 1397-1400.
70. LENTZ MR, KIM JP, WESTMORELAND SV, GRECO JB, FULLER RA, RATAI EM, HE J, SEHGAL PK, HALPERN EF, LACKNER AA, MASLIAH E, GONZÁLEZ RG. Quantitative neuropat hologic correlates of changes in ratio of N-Acetylaspartate to creatine in macaque brain. Radiology 2005; 235: 461-468.
71. STORK C, RENSHAW PF. Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900-919.
72. PETROFF OA. GABA and glutamate in the human brain. Neuroscientist 2002; 8: 562-573.
73. MAGISTRETTI PJ, PELLERIN L. Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann N Y Acad Sci 1996; 777: 380-387.
74. MOFFETT JR, ROSS B, ARUN P, MADHAVARAO CN, NAMBOODIRI AM. N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131.
75. HOANG TQ, BLUML S, DUBOWITZ DJ, MOATS R, KOPYOV O, JACQUES D, ROSS BD. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998; 50: 1033-1040.
76. YAMASUE H, FUKUI T, FUKUDA R, YAMADA H, YAMASAKI S, KUROKI N, ABE O, KASAI K, TSUJII K, IWANAMI A, AOKI S, OHTOMO K, KATO N, KATO T. 1H-MR spectroscopy and gray matter volume of the ante rior cingulate cortex in schizophrenia. Neuroreport 2002; 13: 2133-2137.
77. WOOD SJ, YUCEL M, WELLARD RM, HARRISON BJ, CLARKE K, FORNITO A, VELAKOULIS D, PANTELIS C. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res 2007; 94: 328-331.
78. REID MA, STOECKEL LE, WHITE DM, AVSAR KB, BOLDING MS, AKELLA NS, KNOWLTON RC, DEN HOLLANDER JA, LAHTI AC. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 2010; 68: 625-633.
79. PARDO JV, PARDO PJ, JANER KW, RAICHLE ME. The anterior cingulated cortex mediates processing selection in the Stroop attentional conflict paradigm. Proc Natl Acad Sci USA 1990; 87: 256-259.
80. SIGMUNDSSON T, SUCKLING J, MAIER M, WILLIAMS S, BULLMORE E, GREENWOOD K, FUKUDA R, RON M, TOONE B. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms, Am J Psychiatry 2001; 158: 234-243.
81. CALABRESE DR, WANG L, HARMS MP, RATNANATHER JT, BARCH DM, CLONINGER CR, THOMPSON PA, MILLER MI, CSERNANSKY JG. Cingulate gyrus neuroanatomy in schizophrenia subjects and their non-psychotic siblings. Schizophr Res 2008; 104: 61-70.
82. GALDERISI S, QUARANTELLI M, VOLPE U , MUCCI A, CASSANO GB, INVERNIZZI G, ROSSI A, VITA A, PINI S, CASSANO P, DANELUZZO E, DE PERI L, STRATTA P, BRUNETTI A, MAJ M. Patterns of structural MRI abnormalities in deficit and nondeficit schizoph renia. Schizophr Bull 2008; 34: 393-401.
83. LUI S, DENG W, HUANG X, JIANG L, MA X, CHEN H, ZHANG T, LI X, LI D, ZOU L, TANG H, ZHOU XJ, MECHELLI A, COLLIER DA, SWEENEY JA, LI T, GONG Q. Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. Am J Psychiatry 2009 ; 166: 196-205.
84. KAY SR, OPLER LA, LINDENMAYER JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989; 7: 59-67.
85. MAKRIS N, SEIDMAN LJ, AHERN T, KENNEDY DN, CAVINESS VS, TSUANG MT, GOLDSTEIN JM. White matter volume abnormalities and associations with symptomatology in schizophrenia. Psychiatry Res 2010; 183: 21-29.
86. PREUSS UW, ZETZSCHE T, POGARELL O, MULERT C, FRODL T, MÜLLER D, SCHMIDT G, BORN C, REISER M, MÖLLER HJ, HEGERL U, MEISENZAHL EM. Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms. Psychiatry Res 2010; 183: 133-139.
87. CASCELLA NG, FIELDSTONE SC, RAO VA, PEARLSON GD, SAWA A, SCHRETLEN DJ. Gray-matter abnormalities in deficit schizophrenia. Schizophr Res 2010; 120: 63-70.
88. BERGE D, CARMONA S, ROVIRA M, BULBENA A, SALGADO P, VILAR ROYA O. Gray matter volume deficits and correlation with insight and negative symptoms in first-psychotic-episode subjects. Acta Psychiatr Scand 2011; 123: 431-439.
89. ROTH Y, ZANGEN A, HALLETT M. A coil design for transcranial magnetic stimulation of deep brain regions. J Clin Neurophysiol 2002; 19: 361-370.
90. KRINGELBACH ML, JENKINSON N, OWEN SL, AZIZ TZ. Translational principles of deep brain stimulation. Nat Rev Neurosci 2007; 8: 623-635.
91. BERSANI FS, BIONDI M. Historical recurrences in psychiatry: somatic therapies. Riv Psichiatr. 2012; 47: 1-4.
92. BERSANI FS, MINICHINO A, ENTICOTT PG, MAZZARINI L, KHAN N, ANTONACCI G, RACCAH RN, SALVIATI M, DELLE CHIAIE R, BERSANI G, FITZGERALD PB, BIONDI M. Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: A comprehensive review. Eur Psychiatry 2013; 28: 30-39.
93. LEVKOVITZ Y, RABANY L, HAREL EV, ZANGEN A. Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study. Int J Neuropsychopharmacol 2011; 14: 991-996.
94. MINICHINO A, BERSANI FS, CAPRA E, PANNESE R, BONANNO C, SALVIATI M, DELLE CHIAIE R, BIONDI M. ECT, rTMS, and deepTMS in pharmacoresistant drugfree patients with unipolar depression: a comparative review. Neuropsychiatr Dis Treat 2012; 8: 55-64.
95. BERSANI FS, GIRARDI N, SANNA L, MAZZARINI L, SANTUCCI C, KOTZALIDIS GD, SANI G, DE ROSSI P, RACCAH RN, CALTAGIRONE SS, BATTIPAGLIA M, CAPEZZUTO S, BERSANI G, GIRARDI P. Deep transcranial magnetic stimulation for treatment-resistant bipolar depression: a case report of acute and maintenance efficacy. Neurocase 2013; 19: 451-457.
96. RAPINESI C, KOTZALIDIS GD, SERATA D, DEL CASALE A, BERSANI FS, SOLFANELLI A, SCATENA P, RACCAH RN, BRUGNOLI R, DIGIACOMANTONIO V, CARBONETTI P, FENSORE C, TATARELLI R, ANGELETTI G, FERRACUTI S, GIRARDI P. Efficacy of add-on deep transcranial magnetic stimulation in comorbid alcohol dependence and dysthymic disorder: three case reports. Prim Care Companion CNS Disord 2013; 15 (1). pii: PCC.12m01438.
97. GALYNKER II, COHEN LJ, CAI J. Negative symptoms in patients with major depressive disorder: a preliminary report. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13: 171-176.
98. DELLE CHIAIE R, TRABUCCHI G, GIRARDI N, MARINI I, PANNESE R, VERGNANI L, CAREDDA M, ZERELLA MP, MINICHINO A, CORRADO A, PATACCHIOLI FR, SIMEONI S, BIONDI M. Group Psychoeducation normalizes cortisol awakening response in stabilized bipolar patients under pharmacological maintenance treatment. Psychother Psychosom 2013; 82: 264-266.
99. ISELLA V, MELZI P, GRIMALDI M, IURLARO S, PIOLTI R, FERRARESE C, FRATTOLA L, APPOLLONIO I. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002; 17: 366-371.
100. PLUCK G, BROWN RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636-642.
101. MACRÍ F, MINICHINO A, CAMPI S, MARINO M, PANNESE R, DE MIC HELE F, CAPRA E, TRABUCCHI G, BERSANI FS. [Chronic conversion somatic disorder: a case report]. Recenti Prog Med 2013; 104: 70-72.
102. CORAZZA O, ASSI S, SIMONATO P, CORKERY J, BERSA NI FS, DEMETROVICS Z, STAIR J, FERGUS S, PEZZOLESI C, PASINETTI M, DELUCA P, DRUMMOND C, DAVEY Z, BLASZKO U, MOSKALEWICZ J, MERVO B, FURIA LD, FARRE M, FLESLAND L, PISARSKA A, SHAPIRO H, S IEMANN H, SKUTLE A, SFERRAZZA E, TORRENS M, SAMBOLA F, VAN DER KREEFT P, SCHERBAUM N, SCHIFANO F. Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol 2013; 28: 317-323.
103. REICHMAN WE, COYNE AC, AMIRNENI S, MOLINO BJ, EGAN S. Negative symptoms in Alzheimer's disease. Am J Psychiatry 1996; 153: 424-426.
104. REICHMAN WE,NEGRON A. Negative symptoms in the elderly patient with dementia Int J Geriat Psychiatry 2001 16 S7-S11.
105. GETZ K, HERMANN B, SEIDENBERG M, BELL B, DOW C, JONES J, WOODARD A, RUTECKI P, SHETH R, O'LEARY D, MAGNOTTA V. Negative symptoms in temporal lobe epilepsy. Am J Psychiatry 2002; 159: 644-651.
106. 6) GALYNKER II, DUTTA E, VILKAS N, ONGSENG F, FINESTONE H, GALLAGHER R, SERSENI D, ROSENTHAL RN. Hypofrontality and negative symptoms in patients with dementia of Alzheimer type. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13: 53-59.
107. ASHTON L, BARNES A, LIVINGSTON M, WYPER D. Cingulate abnormalities associated with PANSS negative scores in first episode schizophrenia. Behav Neurol 2000; 12: 93-101.
108. PAULESU E, GOLDACRE B, SCIFO P, CAPPA SF, GILARDI MC, CASTIGLIONI I, PERANI D, FAZIO F. Functional heterogeneity of left inferior frontal cortex as revealed by fMRI. Neuror eport 1997; 8: 2011-2017.
109. PHELPS EA, HYDER F, BLAMIRE AM, SHULMAN RG. FMRI of the prefrontal cortex during overt verbal fluency. Neuroreport 1997; 8: 561-565.
110. CRESPO-FACORRO B, PARADISO S, ANDREASEN NC, O'LEARY DS, WATKINS GL, BOLES PONTO LL, HICHWA RD. Recalling word lists reveals 'cognitive dysmetria' in schizophrenia: a positron emission tomography study. Am J Psychiatry 1999; 156: 386-392.
111. FLETCHER P, MCKENNA PJ, FRISTON KJ, FRITH CD, DOLAN RJ. Abnormal cingulate modulation of frontotemporal connectivity in schizophrenia, Neuroimage 1999; 9: 337-342.
112. FRISTON KJ, FRITH CD, LIDDLE PF, FRACKOWIAK RS. Functional connectivity: the principal component analysis of large (PET) data sets. J Cereb Blood Flow Metab 1993; 13: 5-14.
113. DEVINSKY O, MORRELL MJ, VOGT BA. Contributions of anterior cingulate cortex to behaviour. Brain 1995; 118: 279-306.